ImmunoPEGliposome-mediated reduction of blood and brain amyloid levels in a mouse model of Alzheimer's disease is restricted to aged animals
- 1 January 2017
- journal article
- Published by Elsevier in Biomaterials
- Vol. 112, 141-152
Abstract
No abstract availableKeywords
Funding Information
- European Community's Seventh Framework Programme (FP7/2007-2013, FP7-2009-CT222887, FP7-SP3-People-606950)
This publication has 54 references indexed in Scilit:
- Structure and permeability changes of the blood-brain barrier in APP/PS1 mice: an Alzheimer’s disease animal modelNeurochemical Journal, 2011
- The binding affinity of anti-Aβ1-42 MAb-decorated nanoliposomes to Aβ1-42 peptides in vitro and to amyloid deposits in post-mortem tissueBiomaterials, 2011
- Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's diseaseJournal of Neuroinflammation, 2010
- The human IgM pentamer is a mushroom-shaped molecule with a flexural biasProceedings of the National Academy of Sciences, 2009
- Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's diseaseProceedings of the National Academy of Sciences, 2009
- Amyloid-β immunisation for Alzheimer's diseaseThe Lancet Neurology, 2008
- New Therapeutic Targets in the Neurovascular Pathway in Alzheimer's DiseaseNeurotherapeutics, 2008
- Clearance of amyloid-β by circulating lipoprotein receptorsNature Medicine, 2007
- Global prevalence of dementia: a Delphi consensus studyThe Lancet, 2005
- Natural oligomers of the amyloid-β protein specifically disrupt cognitive functionNature Neuroscience, 2004